missing translation for 'onlineSavingsMsg'
Learn More
Learn More
R&D Systems™ VVD 844
Description
VVD 844 is a potent inhibitor of the PI3K/p110α interaction (IC50 = 4 nM) and the phosphorylated-Ser473-AKT (pAKT) pathway (IC50 = 11 nM). It covalently binds cysteine 242 in the RAS domain of PI3K/p110α and blocks RAS activation of PI3Kα activity in vitro.
In vivo, VVD 844 slows growth of RAS mutant tumors and human epidermal growth factor receptor 2 (HER2)-overexpressing tumors, without causing hyperglycemia. Exhibits synergistic effects with Sotorasib (Cat. No. 7713) and Adagrasib (Cat. No. 7488). VVD 844 is orally bioavailable.
Specifications
Specifications
| Chemical Name or Material | 5-((1R,2S,5S)-2-(2-Chloro-3-fluorophenyl)-3-azabicyclo[3.1.0]hexan-3-yl)-N-((R,E)-4-(methylsulfonyl)but-3-en-2-yl)pyrazine-2-carboxamide |
| CAS | 3080226-63-4 |
| Quantity | 5 mg |
| Product Line | Tocris |
| Target | GTPase Inhibitors |
| Molecular Formula | C21H22ClFN4O3S |
| Purity | 98% |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?